Olaparib
Brand Name: Bracanat* 150
Composition: Olaparib Tablets 150 mg
Manufacturer: Natco Pharma Ltd.
Product Description
Medical Info
Bracanat 150* is a targeted prescription oncology medication containing Olaparib (150 mg). It belongs to a class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors. By blocking the PARP enzyme, it prevents cancer cells from repairing their damaged DNA, ultimately leading to cell death. This treatment is primarily indicated for advanced malignancies, including specific types of ovarian, breast, pancreatic, and prostate cancers, particularly those harboring BRCA genetic mutations. This specialized therapy requires strict oncological supervision to carefully manage dosages and monitor for potential hematological or systemic side effects during treatment.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
